| http://dbpedia.org/ontology/abstract
|
Il veltuzumab è un anticorpo monoclonale che è attualmente studiato per il trattamento del . Sono in corso studi clinici di Fase I/II. Il targer del farmaco è l'antigene . Questo farmaco è sviluppato da , Inc.
, Veltuzumab is a monoclonal antibody (targe … Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity. This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106. In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP). A phase II trial is planned to run for 5 years.se II trial is planned to run for 5 years.
|
| http://dbpedia.org/ontology/casNumber
|
728917-18-8
|
| http://dbpedia.org/ontology/fdaUniiCode
|
BPD4DGQ314
|
| http://dbpedia.org/ontology/wikiPageID
|
19842081
|
| http://dbpedia.org/ontology/wikiPageLength
|
3992
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
992425102
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/Non-Hodgkin%27s_lymphoma +
, http://dbpedia.org/resource/Immune_thrombocytopenia +
, http://dbpedia.org/resource/CD20_antagonist +
, http://dbpedia.org/resource/Orphan_drug +
, http://dbpedia.org/resource/CD20 +
, http://dbpedia.org/resource/Milatuzumab +
, http://dbpedia.org/resource/Monoclonal_antibodies +
, http://dbpedia.org/resource/Immunomedics +
, http://dbpedia.org/resource/Clinical_trials +
, http://dbpedia.org/resource/US_FDA +
|
| http://dbpedia.org/property/atcPrefix
|
none
|
| http://dbpedia.org/property/c
|
6458
|
| http://dbpedia.org/property/casNumber
|
728917
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/h
|
9918
|
| http://dbpedia.org/property/mabType
|
mab
|
| http://dbpedia.org/property/n
|
1706
|
| http://dbpedia.org/property/o
|
2026
|
| http://dbpedia.org/property/s
|
46
|
| http://dbpedia.org/property/source
|
zu/o
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/CD20 +
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
BPD4DGQ314
|
| http://dbpedia.org/property/verifiedfields
|
changed
|
| http://dbpedia.org/property/verifiedrevid
|
470629538
|
| http://dbpedia.org/property/watchedfields
|
changed
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Monoclonals_for_tumors +
, http://dbpedia.org/resource/Template:Monoclonal-antibody-stub +
, http://dbpedia.org/resource/Template:As_of +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Chemspidercite +
, http://dbpedia.org/resource/Template:Drugbankcite +
, http://dbpedia.org/resource/Template:Antineoplastic-drug-stub +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Monoclonal_antibodies +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antibody +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Veltuzumab?oldid=992425102&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Veltuzumab +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q4009438 +
, http://yago-knowledge.org/resource/Veltuzumab +
, http://rdf.freebase.com/ns/m.04q7gb4 +
, http://it.dbpedia.org/resource/Veltuzumab +
, http://dbpedia.org/resource/Veltuzumab +
, https://global.dbpedia.org/id/3iNvt +
|
| rdf:type |
http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/Compound114818238 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
|
| rdfs:comment |
Veltuzumab is a monoclonal antibody (targe … Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity. This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106. In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP). A phase II trial is planned to run for 5 years.se II trial is planned to run for 5 years.
, Il veltuzumab è un anticorpo monoclonale che è attualmente studiato per il trattamento del . Sono in corso studi clinici di Fase I/II. Il targer del farmaco è l'antigene . Questo farmaco è sviluppato da , Inc.
|
| rdfs:label |
Veltuzumab
|
